151 related articles for article (PubMed ID: 38082550)
1. Histone methyltransferase SUV420H1/KMT5B contributes to poor prognosis in hepatocellular carcinoma.
Kato H; Hayami S; Ueno M; Suzaki N; Nakamura M; Yoshimura T; Miyamoto A; Shigekawa Y; Okada KI; Miyazawa M; Kitahata Y; Ehata S; Hamamoto R; Yamaue H; Kawai M
Cancer Sci; 2024 Feb; 115(2):385-400. PubMed ID: 38082550
[TBL] [Abstract][Full Text] [Related]
2. METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN.
Tian QH; Zhang MF; Zeng JS; Luo RG; Wen Y; Chen J; Gan LG; Xiong JP
J Mol Med (Berl); 2019 Nov; 97(11):1535-1545. PubMed ID: 31463732
[TBL] [Abstract][Full Text] [Related]
3. SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and metastasis of hepatocellular carcinoma.
Xu L; Wang P; Feng X; Tang J; Li L; Zheng X; Zhang J; Hu Y; Lan T; Yuan K; Zhang Y; Ren S; Hao X; Zhang M; Xu M
Clin Sci (Lond); 2019 Oct; 133(20):2085-2105. PubMed ID: 31654063
[TBL] [Abstract][Full Text] [Related]
4. Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma.
Zhang Y; Huang J; Li Q; Chen K; Liang Y; Zhan Z; Ye F; Ni W; Chen L; Ding Y
BMC Cancer; 2018 May; 18(1):539. PubMed ID: 29739365
[TBL] [Abstract][Full Text] [Related]
5. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways.
Chen SL; Liu LL; Wang CH; Lu SX; Yang X; He YF; Zhang CZ; Yun JP
Mol Oncol; 2020 Feb; 14(2):373-386. PubMed ID: 31670863
[TBL] [Abstract][Full Text] [Related]
6. Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma.
Fu SJ; Shen SL; Li SQ; Hua YP; Hu WJ; Guo B; Peng BG
BMC Cancer; 2018 Aug; 18(1):815. PubMed ID: 30103712
[TBL] [Abstract][Full Text] [Related]
7. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
9. Long non‑coding RNA MKLN1‑AS aggravates hepatocellular carcinoma progression by functioning as a molecular sponge for miR‑654‑3p, thereby promoting hepatoma‑derived growth factor expression.
Gao W; Chen X; Chi W; Xue M
Int J Mol Med; 2020 Nov; 46(5):1743-1754. PubMed ID: 33000222
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of histone methyltransferase SET8 inhibits progression of hepatocellular carcinoma.
Wu J; Qiao K; Du Y; Zhang X; Cheng H; Peng L; Guo Z
Sci Rep; 2020 Mar; 10(1):4490. PubMed ID: 32161353
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
12. LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway.
Xing Y; Liu Y; Qi Z; Liu Z; Wang X; Zhang H
Cell Mol Biol Lett; 2021 Nov; 26(1):49. PubMed ID: 34837962
[TBL] [Abstract][Full Text] [Related]
13. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
[TBL] [Abstract][Full Text] [Related]
14. Long Noncoding RNA
Gong X; Zhu Z
Cancer Biother Radiopharm; 2020 Jun; 35(5):387-396. PubMed ID: 32315535
[No Abstract] [Full Text] [Related]
15. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
[TBL] [Abstract][Full Text] [Related]
16. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth.
Xu L; Feng X; Hao X; Wang P; Zhang Y; Zheng X; Li L; Ren S; Zhang M; Xu M
J Exp Clin Cancer Res; 2019 Feb; 38(1):98. PubMed ID: 30795787
[TBL] [Abstract][Full Text] [Related]
17. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
18. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
[TBL] [Abstract][Full Text] [Related]
19. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
[TBL] [Abstract][Full Text] [Related]
20. ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
Zhou Z; Jiang H; Tu K; Yu W; Zhang J; Hu Z; Zhang H; Hao D; Huang P; Wang J; Wang A; Xiao Z; He C
J Exp Clin Cancer Res; 2019 Jan; 38(1):18. PubMed ID: 30646949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
